Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

Stopped early · Phase 1

Conditions studied: Small-cell Lung Cancer, Small Cell Lung Carcinoma

In brief

This study will determine the frequency of adverse events (side effects) in patients with relapsed or refractory small cell lung cancer (SCLC) when given nivolumab and irinotecan together followed by nivolumab maintenance. This study will test the safety of the study treatments when given together and see what effect (good or bad) it has on participants and their cancer.

Key facts

Study ID

NCT04173325

Run by

Augusta University

People needed

10

Starts

2020-01-06

Expected to finish

2022-05-26

Last updated by the study team

2022-06-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed SCLC with known UGT1A genotype.
• Patients who have received at least 1 prior platinum-based chemotherapy.
• Life expectancy of 3 months or more.
• Measurable disease.

You may not qualify if…

• Patients with UGT1A polymorphism.
• Currently receiving chemotherapy.
• Pregnant and nursing women.

Where it is running

• Georgia Cancer Center at AU Medical Center — Augusta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.